<?xml version="1.0" encoding="UTF-8"?>
<p>Machamer et al. found 
 <bold>imatinib</bold> (
 <bold>28</bold>), an Abelson kinase signaling pathway inhibitor that could inhibit Abelson tyrosine–protein kinase 2 (Abl2) to block MERS-CoV virion fusion with endosomal membranes with an IC
 <sub>50</sub> value of 10 μM. 
 <bold>28</bold> showed no cytotoxic effects in Vero cells at 100 μM.
 <sup>
  <xref ref-type="bibr" rid="ref123">123</xref>,
  <xref ref-type="bibr" rid="ref124">124</xref>
 </sup> Another Abl inhibitor, 
 <bold>dasatinib</bold> (
 <bold>29</bold>), was active against both MERS-CoV and SARS-CoV, with IC
 <sub>50</sub> values of 5.4 and 2.1 μM, respectively.
 <sup>
  <xref ref-type="bibr" rid="ref125">125</xref>
 </sup>
</p>
